Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice.

Marcel ReiserSteffen DörfelManfred HenselMark HoeslWolf-Oliver JordanMichael KoenigsmannDirk MeyerDietmar ReichertAndreas SchwarzerMoritz MarquardtKerstin KellershohnKathleen Jentsch-Ullrich

Published in: European journal of haematology (2018)

Chemoimmunotherapy with rituximab is feasible and safe in a wide variety of clinical settings in CLL, including the treatment of older patients with comorbidities (ClinicalTrials.gov NCT01178086).

Keyphrases

clinical practice
diffuse large b cell lymphoma
chronic lymphocytic leukemia
squamous cell carcinoma
locally advanced